Skip to main content
Collage of active people enjoying their families and the outdoors.

The WATCHMAN™ Implant

A lifetime of stroke risk reduction, without the lifelong risks of OACs.

One Time. For a Lifetime.

Protection against stroke risk. Protection against oral anticoagulant (OAC) bleed risk. The WATCHMAN Implant is the one-time, minimally invasive procedure that protects your atrial fibrillation (AFib) patients for life.


 

Legs stepping over a fallen bicycle on the ground.


 

500,000+

Over 500,000 AFib patients have left blood thinners behind, replacing OACs with the WATCHMAN Left Atrial Appendage Closure (LAAC) Implant.1

An orange checkbox icon.

Proven1

500,000+

patients

10+

clinical trials

An orange shield icon with a heart in it.

Safe2

99%

implant success rate*

0.5%

major adverse event rate

An orange spinning gear icon.

Effective2

96.2%

of patients discontinued OACs at 45 days


Protect your patients: stroke risk reduction without the risks of OACs

Learn more about the WATCHMAN Implant and hear from cardiologists on this safe, OAC alternative for stroke risk reduction.


 

The world's most studied and implanted LAAC device 


 

Learn more about WATCHMAN

Access resources

Access WATCHMAN resources in the referring HCP download center

Stay connected

Receive monthly updates about the WATCHMAN Implant

Rep visit

Connect with a local representative to learn more about the WATCHMAN Implant


 

Learn how the WATCHMAN Implant works


*Procedure success defined as successful delivery and release of a WATCHMAN FLX Device into the LAA. 

†Occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention. 

References: 

1. Represents all WATCHMAN models. 

2. Kar, S., et al, Primary Outcome Evaluation of the Next Generation LAAC Device: Results from the PINNACLE FLX Trial, Circulation, 2021. 

3. Joglar JA et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2024